EXAGEN INC. (XGN) News
Filter XGN News Items
XGN News Results
|Loading, please wait...|
XGN News Highlights
- XGN's 30 day story count now stands at 17.
- Over the past 24 days, XGN's stories per day has been in a clear downtrend, falling by about -0.82 per 4 days.
- The most mentioned tickers in articles about XGN are CB, SAFE and BIO.
Latest XGN News From Around the Web
Below are the latest news stories about Exagen Inc that investors may wish to consider to help them evaluate XGN as an investment opportunity.
Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases
SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that it will collaborate with Emory University on a new study about the long-term effects of COVID-19 infection in the development of autoimmune diseases. Emory is widely acknowledged as a leading research institution in the study of various autoimmune diseases, including lupus. The longitudinal study will further evaluate the emergence of biomarkers that are known indicators for the development of lupus, rheumatoid arthritis and other autoimmune diseases. This effort will assess the emergence of these biomarkers in mild/moderate COVID patients, among several critical patient groups, includi...
Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten public offering of 4,255,000 shares of its common stock, including 555,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $16.25 per share. The gross proceeds to Exagen from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $69.1 million. Exagen intends to use the net proceeds from the proposed offering for the development of Multi-omics capabilities, including build out of its clinical laboratory, advancement of its product pipeline, incl...
Exagen (XGN) has priced its public offering of 3.7M common shares at $16.25/share, for expected gross proceeds of $60.1M.Underwriters' over-allotment is an additional 555K shares. Net proceeds will be used for build out of clinical laboratory, advancement of its product pipeline, for working capital and other general corporate purposes.Closing date...
Exagen (NASDAQ:XGN) and AnPac Bio-Medical Science (NASDAQ:ANPC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability. Analyst Recommendations This is a breakdown of current ratings and recommmendations for Exagen and AnPac […]
Exagen Inc. (XGN) Q4 2020 Results Earnings Conference Call March 16, 2021, 4:30 9m ET Company Participants Mike Cavanaugh - Investor Relations, Managing Director at Westwicke Partners Ron Rocca - President, Chief Executive Officer Kamal Adawi - Chief Financial Officer Mark Hazeltine - Chief Operating Officer Conference Call Participants Chris...
Exagen (NASDAQ:XGN) posted its quarterly earnings data on Monday. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.13, MarketWatch Earnings reports. Exagen had a negative net margin of 39.49% and a negative return on equity of 29.10%. Shares of XGN opened at $20.30 on Wednesday. The […]
Exagen (NASDAQ:XGN) issued its quarterly earnings data on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.13, MarketWatch Earnings reports. Exagen had a negative net margin of 39.49% and a negative return on equity of 29.10%. Shares of NASDAQ XGN opened at […]
Earlier today, Exagen Inc. released financial results for the quarter and fiscal year ended December 31, 2020. Ron Rocca, president and chief executive officer; Kamal Adawi, chief financial officer; and Mark Hazeltine, chief operating officer, will host this afternoon's call.
Exagen announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…